Guide contents
Open in calculatorCompound briefing
Tesamorelin is a stabilised 44-amino-acid GHRH analogue, FDA-approved as Egrifta for HIV-associated lipodystrophy. It produces a robust GHRH-driven GH/IGF-1 pulse and is the most clinically validated GHRH analogue for visceral adipose tissue (VAT) reduction without compromising subcutaneous fat or lean mass.
The research question
Tesamorelin stimulates endogenous growth-hormone release through the GHRH receptor. Its clinical literature makes it a useful reference point for studying how pituitary signalling, IGF-1 and visceral adipose measurements relate over time.
Mechanism & research themes
Binds pituitary GHRH receptors to stimulate endogenous GH synthesis and release, with downstream IGF-1 elevation. N-terminal modification protects against DPP-4 degradation, extending half-life vs native GHRH.
approximately 18% mean visceral adipose tissue reduction in Phase 3 (LIPO trials)
Improved IGF-1 levels and lipid profile in clinical research
Selective VAT loss without subcutaneous fat or lean mass loss
Preserved insulin sensitivity vs exogenous HGH protocols
Improved sleep architecture and recovery via natural GH pulse
Synergistic when stacked with Ipamorelin or other GHRPs
These are research themes reported across the literature, not established benefits or indications.
Evidence assessment
Controlled human trials support specific clinical applications, particularly visceral adipose changes in studied populations. Those results should not be generalised to unrelated performance or longevity claims.
What to look for
Controlled design, a defined preparation, clinically relevant endpoints and independent replication carry more weight than a single mechanism study.
What not to assume
A plausible pathway does not establish efficacy. Results across different routes, formulations and populations are not automatically interchangeable.
Protocol literature
Standard research/clinical protocols use 1–2mg subcutaneously once daily, typically pre-sleep. Cycles typically run 12–26 weeks with reassessment. Often stacked with a GHRP (e.g. Ipamorelin) for amplified pulse synergy.
Reported persistence
approximately 25–40 minutes plasma; functional GH/IGF-1 elevation persists 12–24 hours.
Calculator starting point
1 mg per reference dose
7 doses per week · 12-week cycle
2 mL default reconstitution volume
Standard research dose 1–2 mg/day SC.
Calculator defaults are editable mathematical reference values, not dosing advice. Verify all calculations independently.
Calculate TesamorelinLaboratory handling
Reconstitution reference
Reconstitute a 5mg vial with 1–2mL bacteriostatic water for a 2.5–5mg/mL working concentration. Swirl gently — do not shake.
Storage reference
Lyophilised: 2–8°C, stable 24 months. Reconstituted: 2–8°C, use within 14–28 days depending on diluent.
Minimum documentation standard
- Record the lot identifier and review its matching analytical documentation.
- Use aseptic technique and record diluent, final volume and calculated concentration.
- Label preparation date, storage conditions and any light or freeze–thaw restrictions.
- Inspect before each use and investigate unexpected colour, clarity or particulate changes.
Limitations & safety
Injection-site reactions (redness, itching, swelling) are common.
Joint pain, peripheral oedema and paraesthesia reported in clinical trials.
Glucose tolerance should be monitored — modest insulin resistance can occur at higher doses.
Research use only
This field note is an educational literature summary, not medical advice or a recommendation for human use. Safety statements are limited by the quality and duration of the available evidence.
Continue reading